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Abstract 
Phencyclidine (PCP) produces cognitive deficits of relevance to schizophrenia in 
animal models.  The aim was to investigate the efficacy of the D1-like receptor 
agonist, SKF-38393, to improve PCP-induced deficits in the novel object recognition 
(NOR) and operant reversal learning (RL) tasks.  Rats received either sub-chronic 
PCP (2 mg/kg) or vehicle for 7 days, followed by a 7-day washout.  Rats were either 
tested in NOR or the RL tasks.  In NOR vehicle rats successfully discriminated 
between novel and familiar objects, an effect abolished in PCP-treated rats.  SKF-
38393 (6 mg/kg) significantly ameliorated the PCP-induced deficit (P<0.01) an effect 
significantly antagonised by SCH-23390 (0.05 mg/kg), a D1-like receptor antagonist 
(P<0.01).  In the RL task sub-chronic PCP significantly reduced performance in the 
reversal phase (P<0.001); SKF-38393 (6.0 mg/kg) improved this PCP-induced deficit, 
an effect antagonised by SCH-23390 (P<0.05).  These results suggest a role for D1-
like receptors in improvement of cognitive function in paradigms of relevance to 
schizophrenia.  
 
 
Keywords D1 receptors; Schizophrenia; Recognition memory; Reversal learning; 
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1. Introduction 
Cognitive dysfunction in schizophrenia is becoming an increasingly important 
therapeutic target as one reason for the residual disability of schizophrenia appears to 
be the long-standing cognitive deficits of the disorder (Green and Nuechterlein, 
2004).  The MATRICS initiative (Measurement and Treatment Research to Improve 
Cognition in Schizophrenia) aims to facilitate the development of better treatments 
targeted at cognition (Marder and Fenton, 2004).  It has been often reported that 
atypical antipsychotics have some beneficial effect on cognitive deficits (Hagger et 
al., 1993; Buchanan et al., 1994; Rossi et al., 1997; Meltzer and McGurk, 1999; 
Harvey et al., 2004).  However, the effect is small (Lieberman, 2006; Keefe et al., 
2007) and hence there remains a great unmet need for novel antipsychotics to improve 
cognitive function.  
There is mounting evidence for the role of dopamine dysregulation in the 
prefrontal cortex (PFC) in schizophrenia (for review see Goldman-Rakic et al., 2004). 
It has been suggested that the negative symptoms and cognitive deficits seen in 
schizophrenia may arise from a dopaminergic deficit in the prefrontal cortex i.e. 
hypofrontality (Davis et al., 1991), whereas the positive symptoms are related to 
hyperactivity of sub-cortical dopaminergic neurons (Grace, 1991).  In keeping with 
this, inhibitors of catechol-O-methyltransferase (COMT), the primary enzyme 
responsible for metabolic degradation of dopamine specifically in the medial 
prefrontal cortex (mPFC), have been shown to improve cortical processing in both 
humans (Apud et al., 2007) and rats (Tunbridge et al., 2006). 
Spano et al. (1978) proposed the existence of two populations of dopamine 
receptors after it was shown that dopamine both stimulated and inhibited adenylate 
cyclase (AC) activity (Brown and Makman, 1972; Kebabian et al., 1972).  D1 and D5 
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receptors belong to the D1-like family in that they stimulate adenylate cyclase (AC), 
whereas D2, D3 and D4 receptors inhibit AC.  D1-like receptors are predominantly 
found in the PFC, while D2-like receptors are expressed in sub-cortical regions (see 
Guillin et al., 2007), although D4 receptors are present in the PFC and hippocampus 
(Lahti et al., 1998).  In keeping with the dopaminergic hypothesis of schizophrenia 
current antipsychotics attenuate positive symptoms by blocking sub-cortical D2 
receptors (Seeman et al., 1975; Creese et al., 1976) but these drugs have, at best, only 
limited efficacy at treating cognitive deficits.   
Mounting evidence suggests that the D1 receptor in the mPFC may be 
important in regulating cognitive function in schizophrenic patients.  Okubo and 
colleagues (1997) reported a down-regulation of D1 binding in the PFC of treatment-
free/-naïve schizophrenic patients.  Another study has demonstrated an association 
between genetic risk for schizophrenia and alterations in cortical D1 receptor binding 
(Hirvonen et al., 2006). It has also been shown that D1 receptors are more abundant 
then D2 receptors in the PFC of non-human primates (Lidow et al., 1991), and this D1 
receptor subfamily has been implicated in working memory functions of the PFC 
(Arnsten et al., 1994, Sawaguchi and Goldman-Rakic, 1991) one aspect of cognition 
impaired in schizophrenia. Thus it is possible that stimulation of the D1 receptor may 
represent a potential strategy for treating cognitive deficits associated with 
schizophrenia.  Indeed, D1 agonists have been highlighted as a molecular target for 
cognitive enhancement in schizophrenia (see Gray and Roth, 2007). 
Phencyclidine (PCP) is a non-competitive NMDA receptor antagonist, which 
has been shown to produce enduring cognitive deficits similar to those observed in 
schizophrenia (Javitt and Zukin, 1991) particularly when administered sub-
chronically rather than acutely (Jentsch and Roth, 1999).  Repeated and intermittent 
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administrations of PCP have been shown to reduce dopamine turnover in the PFC of 
rats and monkeys (Jentsch et al., 1997a,b); moreover, the use of a sub-chronic PCP 
regimen has been suggested to provide a superior pharmacological model of the 
hypodopaminergic state seen in schizophrenia (see Jentsch and Roth, 1999). Sub-
chronic PCP also causes reduced density of parvalbumin-immunoreactive neurons 
(Abdul-Monim et al., 2007) and brain-derived neurotrophic factor (BDNF) levels in 
cortical regions (Snigdha et al., 2007a) in rats.  Indeed the sub-chronic PCP dosage 
regime has been well-validated in our laboratory producing enduring cognitive 
deficits which can be reversed by atypical but not classical antipsychotics in NOR 
(Grayson et al., 2007), reversal learning (Abdul-Monim et al,. 2006, 2007) and 
attentional set-shifting (McLean et al., 2008) tasks. Sub-chronic PCP also produces 
social behaviour deficits in our laboratory which are improved by atypical but not by 
classical antipsychotics (Snigdha and Neill, 2008a; 2008b).  Using this model we have 
observed cognitive deficits in NOR lasting up to 5 months following the last dose of 
PCP (Grayson et al. unpublished observations).  As many atypical antipsychotics 
have affinity for a multitude of receptors, much research is now focusing on 
identifying specific receptor subtypes as potential novel targets and on the 
development of selective compounds (Gray and Roth, 2007) for the treatment of 
cognitive dysfunction in schizophrenia. 
The core aim of this study was to utilise the selective D1-like receptor agents 
SKF-38393 and SCH-23390 to elucidate the role of D1-like receptors in cognition 
using two rodent tests validated in our laboratory, the NOR test and the operant 
reversal learning task, which are both tests highlighted by the MATRICS initiative as 
being relevant translational models for studying visual learning and memory and 
reasoning and problem solving respectively (see Hagan and Jones, 2005).  It is 
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expected that SKF-38393 will ameliorate the sub-chronic PCP-induced deficit, and 
that the antagonist SCH-23390 will block these effects.  Both ligands shall be referred 
to as D1-like throughout as SKF-38393 and SCH-23390 have been reported to have 
similar Ki values at D1 and D5 receptors; SKF-38393 having reported Ki values of 
26nM and 80nM at D1 and D5 receptors respectively (Neumeyer et al., 2003; Qandil 
et al., 2003), whilst SCH-23390 has reported Ki values of 0.37nM and 0.47nM for D1 
and D5 receptors respectively (Lawler et al., 1999). 
We also sought to determine if the stage of oestrous had any effect on reversal 
learning ability since an interaction between gonadal steroids, in particular oestrogen 
and cognitive function has previously been reported (see Cahill, 2006 for review). 
However, we have previously shown no effect of oestrous cycle on novel object 
recognition (Sutcliffe et al., 2007).  It is important for each task to determine whether 
the oestrous cycle has an effect, therefore this was assessed here in reversal learning. 
 
2. Experimental Procedures 
Subjects and housing conditions 
Two cohorts of fifty female hooded-Lister rats, 100 in total (Harlan, UK) housed in 
groups of four or five were used as subjects, rats weighed between 200-250 g.  
Animals were maintained under standard laboratory conditions at a temperature of 
21°C (±2°C) and humidity of 40–50%.  They were maintained on a 12-h/12-h 
light/dark cycle (lights on at 0700 hours) and experimental procedures were 
performed during the light phase.  Cohort 1 were allowed free access to food, while 
cohort 2 prior to operant training and testing, were gradually food deprived to 
approximately 90% of free-feeding body weight; reduced body weight was 
maintained by restricting the amount of food (standard laboratory chow, Special Diet 
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Services, Essex, UK) given to each rat per day (12 g/day). The availability of water 
was not restricted.  Experiments were conducted in accordance with the Animals 
Scientific Procedures Act, UK, 1986, and approved by the University of Bradford 
ethics review process. 
 
Drugs 
The study design involved ten groups (n = 10 per group initially); rats were given 
either 2 mg/kg PCP (n = 80) or vehicle (0.9 % saline; n = 20) by the intraperitoneal 
(i.p.) route twice daily for seven days.  Dosing with sub-chronic PCP or vehicle was 
followed by a washout period of a further seven days.  PCP hydrochloride (Sigma, 
UK) was dissolved in 0.9 % saline.  SKF-38393 hydrochloride (Research 
Biochemicals International, MA, USA) and SCH-23390 hydrochloride (Tocris, UK) 
were dissolved in saline (0.9 %) and were administered via the i.p. route in a volume 
of 1 ml/kg.  SCH-23390 or vehicle was given 20 min prior to SKF-38393 or vehicle 
and rats were tested 30 min following this treatment.  All drug doses were calculated 
as base equivalent weight. 
Hersi and colleagues (1995) showed that a dose of 3.0 mg/kg (i.p.) of SKF-
38393 in male Long-Evans rats increased acetylcholine release by two-fold over 
baseline, thus we carried out a dose response with 3.0 mg/kg as the middle dose (0.75, 
1.5, 3.0, 6.0 mg/kg) in the reversal learning task.  The most efficacious dose (6.0 
mg/kg) was then used in the novel object test.  This dose (6.0 mg/kg) was also shown 
to improve a scopolamine-induced impairment in a T-maze working memory test 
(Amico et al., 2007).  Two doses of SCH-23390 (0.025, 0.05 mg/kg) were tested in 
the NOR experiment to determine which dose was required to antagonise the effect of 
SKF-38393.  Once it was determined that 0.05 mg/kg of SCH-23390 reversed the 
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effect of SKF-38393 only this dose of the antagonist was tested in the second reversal 
learning experiment.  0.05 mg/kg SCH-23390 has also been shown to transiently 
inhibit acetylcholine release (Hersi et al., 1995). 
 
Novel Object Recognition Task 
Cohort 1 was tested in the novel object recognition (NOR) task as described by 
Grayson et al. (2007).  Rats were habituated to the test box for 20 minutes on 3 
consecutive days.  Following a 3-min habituation session on the day of testing each 
rat was placed in the NOR chamber (52 cm wide x 40 cm high x 52 cm long) and 
exposed to two identical objects (A1 and A2) for a period of 3 minutes.  The objects 
used were opaque plastic pyramids, small glass jars, cola cans and striped plastic 
bottles and rats showed equal exploration of these objects in validation experiments in 
our laboratory (Grayson unpublished findings).  The heights of the objects were 
comparable (10 ± 2 cm) and they were heavy enough not to be displaced by the 
animals, to achieve this, some objects were filled with NaCl.  The rats were then 
returned to their home cage for an inter-trial interval of 1 min, the entire box was 
cleaned, both objects removed and one replaced with an identical familiar copy and 
one with a novel object.  Following the ITI, rats were returned to explore the familiar 
(A) and a novel object (B) in the test box for a 3-min retention trial.  The location of 
the novel object in the retention trial was randomly assigned for each rat using a 
Gellerman schedule.  All experiments were filmed and video recorded for subsequent 
behavioural analysis by an experimenter blind to the treatments.  Locomotor activity 
was also recorded; this was evaluated by scoring the total number of sectors or line 
crossings by the animal in both acquisition and retention trials.  The exploration time 
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(E in sec) of each object in each trial was recorded manually using two stopwatches 
and the following factors were calculated. 
The total exploration time of both objects in the acquisition trial (EA1+EA2) 
The total exploration time of both objects in the retention trial (EA+EB).   
Discrimination Index DI = (EB-EA)/(EA+EB) and represents the difference in 
exploration time expressed as a proportion of the total time spent exploring the two 
objects in the retention trial. 
 
Experimental design 
Cohort 1 was used for the novel object recognition test.  Eight rats were used per 
group.  Sub-chronic PCP-treated rats were administered SKF-38393 (6.0 mg/kg, i.p.) 
or vehicle in the presence or absence of SCH-23390 (0.025 and 0.05 mg/kg, i.p.).  
SCH-23390 (0.025 mg/kg, i.p.) was also administered alone.  The drug treatment 
given to each rat (within each home cage) was randomised.   
 
Reversal learning 
Cohort 2 was tested in the reversal learning task as described in detail by Abdul-
Monim et al., 2003 and Idris et al., 2005.  All rats were tested in one of eight operant 
chambers (constructed in-house).  Each chamber (29 × 30 × 30 cm) consisted of 
Plexiglas walls and ceiling, and a metal grid floor over sawdust.  A hinged Plexiglas 
panel (6 × 6 cm) provided access to a food hopper containing food pellets (45 mg 
Noyes pellets, Sandown Scientific, UK).  Two retractable levers (4 × 2 cm) were 
positioned on either side of the food hopper.  A red light emitting diode (LED) was 
positioned centrally above each lever and a house light was located in the ceiling of 
each chamber.  The chambers were placed individually within ventilated sound-
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attenuating hardboard boxes (69 × 38 × 42 cm) containing a Perspex window to allow 
viewing.  A small fan was built into each chamber to mask external noise.  Each 
animal was tested in the same operant chamber throughout the study. All boxes were 
controlled by Med-PC software (Version 2.0 for DOS or Med-PC for Windows, Med 
Associates, Inc. Lafayette, Indiana).  Programmes were written using Medstate 
notation. 
Following habituation to the operant chambers, rats were trained to respond 
for food on a fixed ratio 1 (FR1) schedule of reinforcement with both levers active, as 
previously described (Abdul-Monim et al., 2003).  Rats were trained to press either 
the left or right lever for food delivery according to a visual cue (LED on or off).  The 
experimental session was terminated following a total of 128 lever presses, which 
took approximately 30 min.  Rats were trained once daily for 5 days and this was 
repeated until rats had reached criterion, i.e. 90% correct responding for three 
consecutive days. 
The day before each reversal task session, a full 30-min operant training 
session (as described above) was conducted in order to ensure stable responding, i.e. 
90% correct responding.  The reversal-learning session involved animals being first 
exposed to a 5-min period during which the active lever was the same as on the 
previous training day.  During this period, responses on both correct and incorrect 
levers were recorded.  This part of the session was termed the initial phase.  This was 
followed by a 2-min time-out period, which was signalled by the house light being 
turned off.  The 2-min time-out period acts as a cue that the rule is about to change.  
In the subsequent 5-min period, the active lever was reversed.  Responses made on the 
correct and incorrect levers were again recorded.  This second period was termed the 
reversal phase.  Animals undertook several of these reversal-learning sessions before 
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beginning the drug studies in order to ensure that they attained a stable level of 
performance, i.e. 90% correct responding and at least 25 lever presses in total, in both 
the initial and reversal phases of the task.  
 
Experimental design—drug studies 
Cohort 2 was used for the reversal learning experiments; eight to ten trained rats were 
used per group in the drug studies.  Rats were tested on a cycle of 4 days (previously 
described by Idris et al., 2005).  On day 1 each animal had a 30-min operant training 
session. The following day, animals received the appropriate drug(s) and undertook a 
reversal-learning session. On day 3 and day 4, each animal underwent a further 
operant training session and reversal learning session, respectively, in order to ensure 
that responding was back to normal after the drug treatment.  
The first experiment was carried out before sub-chronic PCP treatment to 
assess the effect of the oestrous cycle in untreated rats.  Vaginal smears were taken 
between 09:00 h and 11:00 h.  This involved the insertion of 0.2 ml of 0.9 % saline 
solution into the vagina by means of a thin plastic pipette.  Histological examination 
of the vaginal lavage was carried out by light microscopy (Finger, 1969).  Each 
sample was classified as being in one of the following phases: pro-oestrus, oestrus, di-
oestrus or met-oestrus.   
Following sub-chronic PCP treatment a dose-response was carried out to SKF-
38393, and this was followed by a further experiment where SCH-23390 was also 
administered in the presence of SKF-38393.  The dose-response to SKF-38393 was 
carried out over 2 experiments, in the first experiment 0.75, 1.5, and 3.0 mg/kg (i.p.) 
were tested followed by a later experiment with 6.0 mg/kg (i.p.) subsequently the data 
were combined which meant there were 20 rats in the vehicle and PCP groups.  The 
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drug treatment given to each rat (and within each home cage) over the course of these 
experiments was randomised.   
 
Data and statistical analysis 
Data for the novel object task i.e. time at novel versus familiar was analysed using 
paired t-tests, and the discrimination indices were compared using a one-way 
ANOVA followed by post-hoc Bonferroni’s multiple comparison test.  Data for 
percentage correct responding in the reversal learning task was calculated using the 
number of presses on the correct lever divided by the total number of presses 
multiplied by 100.  The percent correct responding data was arcsine transformed and 
analysed by one-way ANOVA followed by post-hoc Dunnett’s t-test.  Reversal phase 
performance was compared to initial phase responding using a paired t-test.  The total 
number of lever presses was calculated by adding the correct and incorrect presses 
together within the 5-min test session, this was used to assess whether drugs had 
caused any sedation or behavioural impairment. 
 
3. Results 
Novel object recognition – effects of SKF-38393 and SCH-23390 
There was no significant difference in time spent exploring the two identical objects 
during the acquisition trial in any of the treatment groups (Fig 1a).  In the retention 
trial, vehicle-treated rats explored the novel object significantly more than the familiar 
object (P < 0.05); this effect was abolished in sub-chronic PCP-treated rats (Fig 1b).  
The ability to distinguish between novel and familiar objects was restored following 
administration with SKF-38393 (6.0 mg/kg, i.p.; P < 0.05); this effect was 
antagonised by SCH-23390 at 0.025 and 0.05 mg/kg (i.p.).  SCH-23390 alone had no 
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effect on PCP-treated rats in the retention trial.  A one-way ANOVA revealed a 
significant effect of treatment [F(5,47) = 7.37, P < 0.001] on the discrimination index 
(DI).  The DI for the PCP-treated and SCH-23390 0.025 mg/kg alone groups were 
significantly reduced compared to the vehicle group to -0.05 and -0.07 respectively 
from 0.5 (P < 0.01); SKF-38393 significantly improved the PCP-induced deficit (P < 
0.01) with a DI of 0.5, and this effect was significantly antagonised to -0.08 in the 
presence of SCH-23390 at 0.05 mg/kg (P < 0.01; Fig 1c) but not SCH-23390 at 0.025 
mg/kg (P = 0.216).   There was no effect on locomotor activity assessed by the 
number of line crossings in the initial and retention trials (Fig 1d). 
 
Reversal learning - Effect of oestrous cycle 
There was no significant effect of oestrous cycle on performance of either the initial 
or reversal phases of the reversal learning task (Fig 2) and there was also no effect on 
the total number of lever presses (table 1). 
 
Reversal learning - Effects of SKF-38393 and SCH-23390 
For percentage correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated 
group (P < 0.001) and at SKF-38393 (0.75, 1.5 mg/kg, i.p.; P < 0.05).  A one-way 
ANOVA in the reversal phase showed a significant effect of treatment (F5,78 = 7.38, P 
< 0.001).  Post-hoc analysis revealed that SKF-38393 at 6.0 mg/kg (i.p.) significantly 
improved the PCP-induced deficit (P < 0.05; Fig 3).  There was no significant effect 
on total lever pressing in the initial or reversal phases, suggesting that neither 
locomotor capacity nor motivation were affected (table 2).   
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In a second experiment a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated 
group (P < 0.001; Fig 4).  A one-way ANOVA in the reversal phase showed a 
significant effect of responding (F4,47 = 14.63, P < 0.001).  Post-hoc analysis showed 
that SKF-38393 (6.0 mg/kg, i.p.) significantly improved the PCP-induced deficit (P < 
0.001), and that SCH-23390 (0.05 mg/kg, i.p.) significantly antagonised this effect (P 
< 0.001).  A one-way ANOVA on the total lever pressing in the reversal phase 
showed a significant interaction (F4,47 = 6.14, P < 0.01) and post-hoc analysis showed 
a significant (P < 0.01) reduction in lever pressing following SCH-23390 treatment 
compared to the vehicle group (table 3).   
 
4. Discussion 
In the current set of experiments we examined the efficacy of the D1-like receptor 
agonist, SKF-38398, in improving cognition in two rodent tests of cognitive 
dysfunction of relevance to schizophrenia.  Our data show that SKF-38393 
significantly improved a sub-chronic PCP-induced deficit in the novel object 
recognition and reversal learning tests, an improvement which was subsequently 
antagonised by the D1-like receptor antagonist, SCH-23390.   
Furthermore, we demonstrate that reversal learning is unaffected by the stage 
of the oestrous cycle in our female rats.  This is supported by another study from our 
laboratory showing that stage of oestrous cycle had no effect on episodic memory as 
measured in the NOR task (Sutcliffe et al., 2007).  Sex differences in cognition and 
the role of gonadal steroids, in particular oestrogen and progesterone, is an important 
area of research (Cahill, 2006).  Indeed, we have demonstrated enhanced performance 
of female rats in the NOR task compared with their male counterparts (Sutcliffe et al., 
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2007), an impairment in episodic memory induced by ovariectomy which is restored 
by subsequent administration of oestradiol (Sutcliffe et al., submitted) and an 
interaction between oestradiol and PCP in the NOR task (Sutcliffe et al., 2008).  In 
depth analysis of this subject is beyond the scope of this manuscript, however as 
natural fluctuations in gonadal steroids over the course of the oestrous cycle do not 
affect performance in either the NOR or reversal learning tasks.  There is certainly no 
disadvantage in using females, indeed they confer many advantages to the use of 
males.  For example we have found females to be better at NOR compared with males 
(Sutcliffe et al., 2007), and we have demonstrated that female rats are more sensitive 
to PCP in other cognitive tasks (McLean et al., 2007). 
 In both tests of cognition there was a significant impairment produced by sub-
chronic PCP, as we have consistently demonstrated in NOR (Grayson et al., 2007; 
Neill et al., 2007; Snigdha et al., 2007b) and reversal learning (Abdul-Monim et al., 
2006; 2007; Neill et al., 2008).  In the NOR test vehicle-treated rats explored the 
novel object significantly more than the familiar object in the retention trial, whereas 
PCP-treated rats could not distinguish between the novel and familiar objects, 
suggesting they did not recognise the familiar object.  The mechanism for this effect 
of PCP is not established yet, however recent work from our laboratory showed that 
the PCP-induced deficit is maintained following a 1 hour inter-trial interval and may 
be due to increased susceptibility to distraction during the inter-trial interval (Grayson 
et al., 2008).  In the reversal learning task, the PCP-treated rats were unaffected in the 
initial phase, but demonstrated reduced correct responding in the reversal phase.  This 
suggests that when the rule changes PCP-treated rats do not switch to respond on the 
new correct lever.  We have also demonstrated reduced density of parvalbumin-
immunoreactive neurons in the hippocampus and M1 (motor area 1) region of the 
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frontal cortex following sub-chronic PCP treatment in the rat (Abdul-Monim et al., 
2007).  Sub-chronic PCP also caused significant reductions in brain-derived 
neurotrophic factor (BDNF) levels in several cortical regions (Snigdha et al., 2007a).  
These behavioural and neurochemical data suggest that our sub-chronic PCP dosage 
regimen provides a good clinical correlate as similar findings were demonstrated in 
post-mortem brain tissue analysis from schizophrenic patients (Benes et al., 1991; 
Benes and Berretta, 2001) and in behavioural impairments assessed using the cued 
reinforcement reaction time task (Murray et al., 2008) and the Wisconsin Card 
Sorting Test (Haut et al., 1996; Pantelis et al., 1999). 
 The dopamine D1-like agonist, SKF-38393, significantly improved novel 
object recognition performance and reversal learning ability in the PCP-treated rats.  
In the case of reversal learning, attenuation of the PCP-induced deficit was dose-
dependent.  Administration of the D1-like receptor antagonist SCH-23390 fully 
reversed these improvements in both tests of cognition.  This data is in agreement 
with a study by Granon and colleagues (2000), whereby infusions of SKF-38393 and 
SCH-23390 into the PFC improved and then respectively attenuated accuracy in the 
five-choice attentional task.  Hersi and co-workers (1995) found that SKF-38393 
improved cognitive performance in the Morris water maze in rats with age-related 
impairments.  In the current study we have used a sub-chronic PCP regimen to induce 
schizophrenia-like deficits in cognition, however, amphetamine can also induce 
cognitive impairments in tests of working memory (Castner et al., 2005), attentional 
set-shifting (Fletcher et al., 2005), and reversal learning (Idris et al., 2005).  A study 
by Fletcher and colleagues found that amphetamine-induced impairments were 
reversed by infusing SKF-38393 into the mPFC (Fletcher et al., 2007).  This effect of 
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SKF-38393 to improve cognitive function in amphetamine-treated rats is in agreement 
with the effect observed in our sub-chronic PCP-treated rats. 
It is important to note that we have examined the effect of SCH-23390 alone 
in PCP-treated rats in order to eliminate the possibility that SCH-23390 could have 
affected cognitive performance alone.  In the reversal learning task, it appears that 
there was a small but non-significant effect of SCH-23390 (0.05 mg/kg) to impair 
performance in the initial phase, an effect not observed following sub-chronic PCP 
treatment alone.  This trend was supported by a study showing that intracortical 
infusions of SCH-23390 impaired performance accuracy in the five-choice attentional 
task (Granon et al., 2000).  Therefore, blockade of D1-like receptors with SCH-23390 
alone may impair cognition, but this was not observed in the current experiments. 
SKF-38393 also has an affinity for 5-HT2C receptors (then classified as 5-
HT1C; Briggs et al., 1991), albeit reduced affinity compared with D1-like receptors.  It 
is unlikely that 5-HT2C receptors play a critical role in the effects of SKF-38393 as its 
effects in both tasks were fully reversed by SCH-23390 which has been shown to be 
selective for D1-like receptors, however further experiments are required to 
investigate this possibility since 5-HT2C receptor agonists do show efficacy in pre-
clinical tasks of cognition (Siuciak et al., 2007).  It was previously shown that 3.0 
mg/kg of SKF-38393 increased acetylcholine (ACh) release by two-fold over baseline 
(Hersi et al., 1995), although the improvement in reversal learning induced by this 
dose did not reach statistical significance in the current study.  However, the most 
efficacious dose in our reversal learning experiment was 6.0 mg/kg; this dose was also 
shown to improve a scopolamine-induced impairment in a T-maze working memory 
test (Amico et al., 2007).  In our NOR experiment it was demonstrated that the most 
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efficacious dose of SCH-23390 was 0.05 mg/kg, and this dose has also been shown to 
transiently inhibit acetylcholine release (Hersi et al., 1995).  
Cognitive impairments observed in the Wisconsin Card Sorting Task 
(Kashima, 1991) were positively correlated with a down-regulation of D1 binding in 
the PFC of treatment-free/-naïve schizophrenic patients (Okubo et al., 1997); thus 
identifying the D1 receptor as a particularly relevant target for schizophrenia (Gray 
and Roth, 2007).  The prefrontal cortex is critically involved in reversal learning; it 
has been shown more specifically that lesions of the orbital PFC impair reversal 
learning ability (McAlonan and Brown, 2003; Tait and Brown, 2007).  Damage to the 
PFC has also been shown to impair recognition memory tasks (Kolb et al., 1994; 
Meunier et al., 1997).  The hippocampus is also a critical brain region for learning and 
memory.  The density of D1 receptors is considerably higher than D2 receptors 
throughout the cortex with differential distribution in the rat mPFC (Vincent et al., 
1995), and low levels of D2 receptors have been detected in the hippocampus 
(Meador-Woodruff et al., 1989; Levey et al., 1993).  The majority of dopamine 
receptors in the hippocampus are from the D1-like subfamily of receptors (Dawson et 
al., 1986), with a high density of the D5 receptor (Ciliax et al., 2000).  Furthermore, it 
has been reported that administration of SKF-38393 increased hippocampal 
acetylcholine (ACh) release in young and aged rats (Hersi et al., 1995), which 
improved performance in the Morris water maze, thus suggesting a mechanism for the 
cognitive enhancing effects of SKF-38393.  Dihydrexidine, a full D1-like receptor 
agonist has been shown to increase extracellular concentrations of cortical ACh to 
around 300% of baseline values; an effect which was completely blocked by SCH-
23390, and coincided with an improvement in cognitive performance assessed using a 
passive-avoidance paradigm (Steele et al., 1997).  Indeed, it has also been 
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demonstrated that atypical antipsychotics such as clozapine, olanzapine, risperidone 
and ziprasidone can increase levels of ACh in the mPFC (Ichikawa et al., 2002).  This 
suggests a beneficial mechanism of action in that D1-like agonists could improve 
cognition in a similar manner to some atypical antipsychotics. 
Positive symptoms are induced by elevation of dopamine in the limbic system, 
whereas negative and cognitive symptoms are due, at least in part, to decreased 
dopamine prefrontal function (Davis et al., 1991).  As agents which increase 
prefrontal dopamine turnover may have beneficial effects on cognition it would seem 
profitable to explore direct stimulation of the D1 receptor in the PFC.  Indeed, D1 
agonists have been highlighted as a molecular target for cognitive enhancement in 
schizophrenia (see Gray and Roth, 2007).  Subsequently, a single administration of 
the full D1-like receptor agonist, dihydrexidine, produced increased perfusion in D1 
rich PFC regions in patients with schizophrenia (Mu et al., 2007); suggesting that 
agents increasing transmission at dopamine D1 receptors could have potential in the 
pharmacotherapy of schizophrenia through a variety of mechanisms.  However, the 
use of D1 receptor agonists as therapeutic agents poses difficulties for 
pharmacologists as dopamine function in the PFC seems to follow an “inverted-U” 
dose-response relationship whereby increases or decreases from an optimal level 
result in cognitive impairment (Goldman-Rakic et al., 2000).  In addition, chronic 
treatment with D1 agonists may lead to the down-regulation of D1 receptors which 
could in turn worsen cognition.  Though these limitations have been identified, a 
sensitising regimen of D1 agonist treatment has substantial potential for providing an 
adjuvant treatment.  Currently, the full D1 agonist dihydrexidine (DAR-0100) is in 
clinical trials for this indication (George et al., 2007). 
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In conclusion, in the present study we have demonstrated that the D1-like 
agonist, SFK-38393, improves a PCP-induced deficit in both the novel object 
recognition and the reversal learning tests.  The cognitive enhancing effect of SFK-
38393 in both tests was significantly antagonised by the D1-like receptor antagonist 
SCH-23390.  These data provide evidence supporting the role of D1-like receptors in 
improvement of cognitive deficits in schizophrenia as recently proposed by Goldman-
Rakic et al., 2004. 
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Tables 
 
 
Table 1: The influence of stage of the oestrous cycle on total lever pressing. 
Stage of cycle Initial phase Reversal phase 
Di-oestrous 29.1 0.3 28.0 0.4 
Met-oestrous 28.4 0.6 29.0 0.5 
Pro-oestrous 28.4 0.2 28.3 0.3 
Oestrous 28.7 0.3 28.5 0.4 
 
 
Table 2: The effect of SKF-38393 on total lever pressing. 
Drug treatment Initial phase Reversal phase 
vehicle + vehicle 27.0 0.3 27.0 0.2 
vehicle + sub-chronic PCP 26.9 0.2 26.6 0.2 
0.75 mg/kg + sub-chronic PCP 25.9 0.3 26.3 0.2 
1.5 mg/kg + sub-chronic PCP 26.1 0.2 26.1 0.2 
3.0 mg/kg + sub-chronic PCP 25.8 0.3 26.0 0.1 
6.0 mg/kg + sub-chronic PCP 26.8 0.5 27.3 0.4 
 
 
Table 3: The effect of SKF-38393 and SCH-23390 on total lever pressing. 
Drug treatment Initial phase Reversal phase 
vehicle + vehicle 27.9 0.5 26.9 0.3 
vehicle + sub-chronic PCP 27.0 0.4 26.9 0.4 
6.0 mg/kg SKF38393 + sub-chronic PCP 26.1 0.6 27.8 0.4 
0.05 mg/kg SCH23390 + sub-chronic PCP   24.2 1.5*       20.2 2.1*** 
0.05 mg/kg SCH23390 + 6.0 mg/kg 
SKF38393 + sub-chronic PCP 
25.0 0.9 24.6 1.6 
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Fig 1c 
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Fig 1d 
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Fig 2 
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Fig 3 
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Fig 4 
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Table and Figure Legends 
 
Table 1: The effect of stage of the oestrous cycle on the total number of lever presses 
in the reversal learning paradigm.  Data are expressed as the mean  sem total number 
of lever presses (n=6-9 per group) in the initial and reversal phase of the task. 
 
Table 2: The effect of SKF-38393 (0.75, 1.5, 3.0, 6.0 mg/kg) and sub-chronic PCP 
(2.0 mg/kg, twice a day for 7 days, i.p.) on the total number of lever presses in the 
reversal learning paradigm.  Data are expressed as the mean  sem total number of 
lever presses (n=9-20 per group) in the initial and reversal phase of the task. 
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Table 3: The effect of SKF-38393 (6.0 mg/kg), SCH-23390 (0.05 mg/kg) and sub-
chronic PCP (2.0 mg/kg, twice a day for 7 days, i.p.) on the total number of lever 
presses in the reversal learning paradigm. Data are expressed as the mean  sem total 
number of lever presses (n=9-10 per group) in the initial and reversal phase of the 
task.  Dunnett’s t-test showed a significant reduction in lever pressing compared to 
vehicle (*P<0.05, ***P=0.001). 
 
Figure 1a: The effect of treatment with vehicle or SCH-23390 (0.025, 0.05 mg/kg, 
i.p., 30 min prior to testing) followed by treatment with vehicle or SKF-38393 (6 
mg/kg, i.p., 20 min prior to testing) on the effect of sub-chronic PCP (2.0 mg/kg, 
twice daily for 7 days, i.p.) in the acquisition phase of the novel object recognition 
task.  Data are shown as mean ± s.e.m of time spent exploring the objects (n=8 per 
group). 
 
Figure 1b:  The effect of treatment with vehicle or SCH-23390 (0.025, 0.05 mg/kg, 
i.p., 30 min prior to testing) followed by treatment with vehicle or SKF-38393 (6.0 
mg/kg, i.p., 20 min prior to testing) on the deficit produced by sub-chronic PCP (2.0 
mg/kg, twice daily for 7 days, i.p.) in the retention phase of the novel object 
recognition task.  Data are shown as mean ± s.e.m of time spent exploring the objects 
(n=8 per group).  Paired t-tests showed that the exploration time of the novel object 
was significantly greater then the familiar object (*P<0.05). 
 
Figure 1c: The effect of treatment with vehicle or SCH-23390 (0.025, 0.05 mg/kg, 
i.p., 30 min prior to testing) followed by treatment with vehicle or SKF-38393 (6.0 
mg/kg, i.p, 20 min prior to testing) on the deficit produced by sub-chronic PCP (2.0 
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mg/kg, twice daily for 7 days, i.p.) in the novel object recognition task.  Data are 
shown as mean DI ± s.e.m (n=8 per group). The discrimination indices were analysed 
by post-hoc Bonferroni’s multiple comparison test.  The DI for the PCP-treated group 
and SCH-23390 alone were significantly impaired compared to the vehicle group 
(**P<0.01), SKF-38393 significantly improved the PCP-induced deficit (
##
P<0.01), 
and this effect was significantly blocked in the presence of SCH-23390 at 0.05 mg/kg 
(
++
P<0.01). 
 
 
Figure 1d: The effect of treatment with vehicle or SCH-23390 (0.025, 0.05 mg/kg, 
i.p., 30 min prior to testing) followed by treatment with vehicle or SKF-38393 (6.0 
mg/kg, i.p, 20 min prior to testing) on the deficit produced by sub-chronic PCP (2.0 
mg/kg, twice a day for 7 days, i.p.) on locomotor activity (line crossings) in the novel 
object recognition task.  Data are shown as mean line crossings ± s.e.m (n=8 per 
group).  
 
Figure 2: The influence of stage of the oestrous cycle on performance of the reversal 
phase of the reversal learning task.  Data are shown as mean ± s.e.m. of percent 
correct responding (n = 6-9).  Stages of the cycle were defined as di-oestrous (D), 
met-oestrous (M), pro-oestrous (P) and oestrous (O).  No significant differences 
between the groups in the initial phase or reversal phases. 
 
Figure 3: The effect of SKF-38393 (0.75, 1.5, 3.0, 6.0 mg/kg) on the deficit produced 
by sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the 
reversal phase of the reversal learning task.  Data are shown as mean ± s.e.m. of 
percent correct responding (n=9-20).  A paired t-test showed a significant reduction in 
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performance of the reversal phase compared with the initial phase; 
###
P<0.001, 
#P<0.05.  Dunnett’s t-test showed significant improvement in responding compared to 
PCP alone in the reversal phase at 6.0 mg/kg of SKF-38393; *P<0.05. 
 
Figure 4: The effect of SKF-38393 (6.0 mg/kg) and SCH-23390 (0.05 mg/kg) on the 
deficit produced by sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on 
performance of the reversal phase of the reversal learning task.  Data are shown as 
mean ± s.e.m. of percent correct responding (n=9-10).  Significant reduction in 
performance of the reversal phase compared with the initial phase (
###
P<0.001).  Post-
hoc Bonferroni’s multiple comparison test showed that SKF-38393 (6.0 mg/kg) 
significantly improved the PCP-induced deficit (***P<0.001), and that this deficit 
was significantly antagonised by SCH-23390 (0.05 mg/kg); 
+++
P<0.001. 
 
 
 
